Table 4.
Patients’ characteristics for NK- and TH1-cells
| RTX | RRMS | HC | |
|---|---|---|---|
| Number of patients | 25 | 25 | 25 |
| Gender (female) | 17 | 16 | 16 |
| Age (years) | 40 ± 8.7 | 39 ± 10 | 36 ± 8.2 |
| Disease duration (years) | 6.4 ± 5.9 | 5.3 ± 4.7 | |
| Treatment at date of analysis | Rituximab | DMF | None |
| EDSS at date of analysis | 4.3 ± 2.9 | 4.5 ± 1.9 |
Data are expressed as mean ± SD where appropriate
DMF dimethyl fumarate, EDSS Expanded Disability Status Scale, HC healthy control, n number of patients, NMO neuromyelitis optica, NMOSD neuromyelitis optica spectrum disease, RRMS relapsing–remitting MS, RTX rituximab, SPMS secondary progressive MS